Tyra Biosciences, Inc. (TYRA)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

19.94 on 9 Oct 2026

1 buy1 sale at will10 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$119.95M

Free cash flow

$95.28M

Return on equity

-46.3%

Return on capital

-40.5%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
9 Sep 2026	Verjee Rehan Director	Bought	$20.00K	opened
25 Mar 2026	KAPLAN GILLA Director	Sold at will	$528.51K	33.6%
12 Feb 2026	Bensen Daniel Chief Discovery Officer	Sold on a plan	$262.96K	5.2%
12 Jan 2026	Bensen Daniel Chief Discovery Officer	Sold on a plan	$228.19K	4.9%
19 Dec 2025	MORE ROBERT J Director	Sold on a plan	$250.00K	0.3%
12 Dec 2025	Bensen Daniel Chief Discovery Officer	Sold on a plan	$181.16K	4.7%

32out of 100

Profitability 0

Financial strength 60

Growth n/a

Insiders 45

Strongest on financial strength (60), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$20.00K

1 buy, 1 buyer

Sold

$10.59M

11 sales

Planned sales

91%

under a 10b5-1 plan